Vascular Biogenics Ltd (NASDAQ:VBLT) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $1.25 and last traded at $1.27, with a volume of 2225 shares. The stock had previously closed at $1.38.

Several equities research analysts recently issued reports on the stock. HC Wainwright reissued a “hold” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research report on Monday, August 20th. Zacks Investment Research raised shares of Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Thursday, August 23rd. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Vascular Biogenics currently has a consensus rating of “Hold” and an average target price of $2.94.

The company has a current ratio of 10.45, a quick ratio of 10.45 and a debt-to-equity ratio of 0.01. The firm has a market cap of $49.52 million, a P/E ratio of -3.43 and a beta of -1.25.

Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings results on Thursday, August 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. The business had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.30 million. As a group, analysts forecast that Vascular Biogenics Ltd will post -0.69 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Vascular Biogenics (VBLT) Hits New 12-Month Low at $1.25” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at

Vascular Biogenics Company Profile (NASDAQ:VBLT)

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

See Also: What do investors mean by earnings per share?

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.